Beyond Air to Participate in the D. Boral Capital Global Conference 2026
Beyond Air (NASDAQ: XAIR) announced that CEO Robert Goodman and CFO Dan Moorhead will participate in the D. Boral Capital Global Conference 2026 on May 7, 2026 at The Plaza Hotel in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beyond Air (NASDAQ: XAIR) announced that CEO Robert Goodman and CFO Dan Moorhead will participate in the D. Boral Capital Global Conference 2026 on May 7, 2026 at The Plaza Hotel in New York.
The company will hold one-on-one meetings with investors; interested parties should contact their D. Boral Capital representative to request scheduling.
Details
News Market Reaction – XAIR
On Apr 15, the day this news came out, XAIR closed 11.58% below the previous close.
Data tracked by StockTitan Argus for the Apr 15 session.
Key Figures
- Q3 2026 Revenue
- $2.2 million
- Fiscal third quarter 2026 revenue from 8-K/10-Q
- Revenue Growth
- 105%
- Year-over-year revenue increase in fiscal Q3 2026
- Net Loss
- $7.3 million
- Fiscal Q3 2026 net loss attributable to common stockholders
- Cash & Securities
- $17.8 million
- Cash, equivalents, restricted cash and marketable securities as of Dec 31, 2025
- Long-term Debt
- $22.0 million
- Total long-term debt reported in 8-K/10-Q
- Revenue Guidance
- $8–10 million
- Maintained fiscal 2026 revenue guidance from 8-K
- Accumulated Deficit
- $309.3 million
- Accumulated deficit as of Dec 31, 2025 from 10-Q
- Shares Outstanding
- 10,529,344
- Common shares outstanding as of Feb 10, 2026
Historical Context
-
National GPO deal expanding LungFit PH access to nearly 2,000 hospitals.
-
CEO transition from Steve Lisi to Robert Goodman to lead commercialization.
-
Interim Phase 1 UNO data showing early activity and favorable safety profile.
-
Announcement of participation in the 38th Annual Roth investor conference.
-
Termination of planned NeuroNOS sale while retaining and reassessing the asset.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nitric oxide medical
nasdaq financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York.
| Conference | ||
| Format: | One-on-one meetings | |
| Conference Dates: | May 7th | |
| Participants: | Robert Goodman, CEO, and Dan Moorhead, CFO of Beyond Air | |
If you are interested in requesting a one-on-one meeting at the conference, please contact your D. Boral Capital representative to schedule accordingly.
About Beyond Air, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s expectations related to the commercial growth, market adoption of LungFit PH, expansion in the U.S. and international markets, and the Company’s long-term strategic and financial performance. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,” “could,” “may,” and similar expressions, or by the use of future tense. These statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management.
Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully execute its commercial strategy, achieve market adoption of its products, maintain and expand customer relationships, manage leadership transitions effectively, obtain additional financing, and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.
CONTACTS:
Investor Relations contact
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.